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Reducing the population requiring interventions against 
lymphatic ﬁ lariasis in Africa
The slow progress in endemicity mapping of neglected 
tropical diseases (NTDs) in Africa and scaling up of mass 
drug administration (MDA) in all endemic countries 
has hampered eﬀ orts to meet the London Declaration’s 
2020 elimination and control targets. Lymphatic 
ﬁ lariasis is targeted to be eliminated by 2020; but by the 
end of 2012, 11 of the 73 countries currently endemic 
for the disease had not completed the endemicity 
mapping to deﬁ ne the true number of people requiring 
interventions. Ten of the 11 partly mapped or unmapped 
countries were in Africa, where 35 countries are known 
to be endemic for this disease. 
Lymphatic ﬁ lariasis is a high-burden, mosquito-
borne NTD that aﬀ ects 1·1 billion people worldwide.1 
In Africa, the number of people requiring treatment 
for lymphatic ﬁ lariasis in the 35 endemic countries 
decreased from 472·1 million in 2013, to 409·7 million 
in 2014. The reduction is partly due to a reassessment of 
the at-risk population through a renewed, large-scale, 
and accelerated endemicity mapping or remapping 
exercise to accurately establish the burden of NTDs in 
the region. Mapping in previously only partly mapped 
or unmapped countries was initiated in 2013 by WHO’s 
Regional Oﬃ  ce in Africa, using reﬁ ned survey methods.1 
We argue that with endemicity mapping still ongoing in 
the high-burden countries of the Democratic Republic 
of Congo (49·1 million people at risk of infection), 
Nigeria (114·3 million), and Tanzania (45·9 million),1 the 
true number of people requiring interventions against 
lymphatic ﬁ lariasis could be much lower than current 
estimates.  
Elimination of lymphatic ﬁ lariasis as a public health 
problem by 2020 will be achieved mainly through 
preventive chemotherapy, based on annual MDA to 
entire eligible populations living in implementation 
units (usually a district) where lymphatic ﬁ lariasis is 
endemic (ie, if one person is reportedly positive for the 
disease after surveying two communities, examining 
about 100 people per community—ie, rate of microﬁ laria 
or circulating ﬁ larial antigen [CFA] is ≥1% in either 
community).2 On completion of mapping in Ethiopia 
in 2013, the population requiring MDA decreased 
from 30 million to 11 million people.3 In 2014, after 
resurveying endemic districts that never started MDA 
for this disease, Tanzania reclassiﬁ ed 63 districts as non-
endemic, and the at-risk population decreased from 
39·9 million to 26·5 million people.1 Remapping surveys 
completed in Gambia4 and Gabon5 reported no evidence 
for lymphatic ﬁ lariasis transmissions in the countries 
where, altogether, 2·5 million people were estimated to 
be at risk. The number of people requiring interventions 
against lymphatic ﬁ lariasis in Ethiopia could be less 
than the current estimate of 11 million because 
45 of the 75 newly endemic implementation units 
had borderline results of one CFA-positive individual 
per implementation unit.3 The 2015 remapping of 
13 low-endemicity implementation units with borderline 
results in Ethiopia and Tanzania, using a new remapping 
method, did not show active transmission in 12 of 
the 13 implementation units;6 hence the reduction in the 
at-risk population in Tanzania. Remapping is ongoing 
for the 45 implementation units with borderline results 
in Ethiopia. In the Democratic Republic of Congo where 
lymphatic ﬁ lariasis is coendemic with loiasis, the CFA 
card test might not be reliable, and CFA prevalence could 
be overestimated in areas highly endemic for loiasis.7
Vector control methods—eg, residual spraying and 
sleeping under long-lasting insecticidal nets to combat 
malaria—led to signiﬁ cant reductions or interruption 
of lymphatic ﬁ lariasis transmission by Anopheles 
mosquitoes in the Solomon Islands, Papua New Guinea, 
and Togo.8 A recent endemicity remapping survey 
done in the previously lymphatic ﬁ lariasis endemic 
Gambia showed no evidence for ongoing transmission.4 
Recent entomological and CFA surveys did not show 
evidence for lymphatic ﬁ lariasis  transmission in the 
national capitals of Liberia (Monrovia) and Sierra 
Leone (Freetown) where about 2·4 million people 
are considered at risk based on the presence of CFA 
positives only. Lymphatic ﬁ lariasis is now virtually 
absent along the shores of Lake Victoria where it was 
endemic in the early 1900s before the implementation 
of dichlorodiphenyltrichloroethane (DDT) spraying 
against human African trypanosomiasis (HAT).9 After 
the discovery of DDT in 1945, residual spraying was used 
as the main strategy against HAT in Africa for more than 
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40 years. Residual spraying was done in areas previously 
endemic for lymphatic ﬁ lariasis including southern 
Uganda, eastern Kenya, and northern Tanzania, which 
are now all non-endemic.10 Many unmapped areas in 
Botswana, Nigeria, and Zimbabwe could also be free of 
lymphatic ﬁ lariasis transmission because vast areas were 
exposed to residual spraying against HAT for several 
years in the 1970s and 1980s. In Zimbabwe and Nigeria, 
residual spraying activities in 10 years covered between 
148 000 km² and 210 000 km² of land.10
In addition to the eﬀ ect of vector control against 
malaria and HAT on lymphatic ﬁ lariasis endemicity over 
several years, recent improvements in NTD mapping 
strategies and diagnosis of Loa loa have greatly aﬀ ected 
the outcomes of surveys undertaken to establish the 
burden of NTDs in Africa. More accurate mapping 
eﬀ orts, revealing lower than previously thought 
numbers of individuals requiring interventions, should 
give renewed impetus to eﬀ orts to meet the 2020 target 
for elimination of lymphatic ﬁ lariasis. 
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